Skip to main content

Advertisement

SpringerLink
Log in

Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) frequently occurs in many human cancers and hampers their therapeutic use. A large body of evidence has demonstrated the pro-survival role of autophagy in many human cancers. However, whether autophagy is involved in the induction of erlotinib resistance in tongue squamous cell carcinoma (TSCC) remains unknown. In this report, we found that autophagy prior to or induced by erlotinib treatment plays an important role in erlotinib resistance in tongue cancer cells. Using LC3 transfection, we observed that autophagy is upregulated and further induced when treated with erlotinib. Moreover, we found that autophagy plays a cytoprotective role by MTT analysis of the cell viability in TSCCs when treated with rapamycin or hydroxychloroquine (HCQ) in combination with erlotinib. However, 3-methyladenine (3-MA) did not influence the autophagy. Then, through siRNA technology and WB, we found that erlotinib-induced autophagy is mediated by ATG5 but not Beclin1. Also, knockdown of ATG5 significantly decreased the erlotinib resistance and knockdown of Beclin1 did not affect the sensitivity to erlotinib in TSCCs. Taken together, this indicates the critical role of non-canonical autophagy in erlotinib resistance in TSCCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Zhang S, Feng XL, Shi L, Gong CJ, He ZJ, Wu HJ, et al. Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma. Oncol Rep. 2013;29(5):1819–26.

    CAS  PubMed  Google Scholar 

  2. Feaver GP. Oral cancer in the UK: to screen or not to screen. Oral Oncol. 1999;35(4):450.

    Article  CAS  PubMed  Google Scholar 

  3. Atula S, Grenman R, Laippala P, Syrjanen S. Cancer of the tongue in patients younger than 40 years. A distinct entity? Arch Otolaryngol Head Neck Surgery. 1996;122(12):1313–9.

    Article  CAS  Google Scholar 

  4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–54.

    Article  CAS  PubMed  Google Scholar 

  5. Metzger B, Chambeau L, Begon DY, Faber C, Kayser J, Berchem G, et al. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet. 2011;12:144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lindeman N. Keynote lecture: KN01 EGFR and beyond: evolution of molecular classification of lung cancer. Pathology. 2014;46 Suppl 2:S1.

    Article  CAS  Google Scholar 

  8. Caiazza F, Elliott L, Fennelly D, Sheahan K, Doherty GA, Ryan EJ. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomark Med. 2015;9(4):363–75.

    Article  CAS  PubMed  Google Scholar 

  9. Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O. MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol. 2013;139(10):1615–24.

    Article  CAS  PubMed  Google Scholar 

  10. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med. 2008;359(17):1834–6.

    Article  CAS  PubMed  Google Scholar 

  11. Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013;14(8):e302–309.

    Article  CAS  PubMed  Google Scholar 

  12. Tan DS, Wang W, Leong HS, Sew PH, Lau DP, Chong FT, et al. Tongue carcinoma infrequently harbor common actionable genetic alterations. BMC Cancer. 2014;14:679.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL. EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK. Transl Oncol. 2012;5(5):327–34.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131(1):80–90.

    Article  CAS  PubMed  Google Scholar 

  15. Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Kostler WJ, et al. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene. 2012;31(30):3505–15.

    Article  CAS  PubMed  Google Scholar 

  16. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(8):2260–9.

    Article  CAS  Google Scholar 

  17. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(15):2442–9.

    Article  CAS  Google Scholar 

  18. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res: Off J Am Assoc Cancer Res. 2001;7(5):1459–65.

    CAS  Google Scholar 

  19. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(22):5007–18.

    Article  CAS  Google Scholar 

  20. Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget. 2013;4(4):550–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene. 2013;32(33):3846–56.

    Article  CAS  PubMed  Google Scholar 

  22. Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, et al. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science. 2012;338(6109):956–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Martin TD, Chen XW, Kaplan RE, Saltiel AR, Walker CL, Reiner DJ, et al. Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. Mol Cell. 2014;53(2):209–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118(12):3917–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(12):3198–210.

    Article  CAS  Google Scholar 

  27. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara Jr PN, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014;33(36):4521–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Shien K, Yamamoto H, Soh J, Miyoshi S, Toyooka S. Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. Acta Med Okayama. 2014;68(4):191–200.

    PubMed  Google Scholar 

  29. Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(15):4059–74.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Stomatology, Liaoning Medical University, 3-40 Songpo Road, Jinzhou, 121000, Liaoning, People’s Republic of China

    Keqiang huang

  2. School of Stomatology Shandong University, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Shandong University, Jinan, 250012, China

    Keqiang huang & Dongxu liu

Authors
  1. Keqiang huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongxu liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dongxu liu.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

huang, K., liu, D. Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer. Tumor Biol. 37, 9625–9633 (2016). https://doi.org/10.1007/s13277-015-4689-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4689-z

Keywords

Search

Navigation